Aspargo Labs’ business model is repeatable and applies our proprietary technology to the world’s most meaningful compounds and brands.
Current and near-term projects have strong IP protection through 2036, including Oral Suspension for Sildenafil (VIAGRA®) through 2036.
Multiple patents granted for future digitally connected drug delivery device.
Aspargo Labs has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) as part of the process to become a publicly traded company. This filing includes details about the company’s business, financials, and the proposed listing of our shares on the New York Stock Exchange.
You can view the filed S-1 registration statement on the SEC’s database HERE.
Stay informed with our latest updates:
NEW YORK, December 20, 2024 – Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s
Life sciences marketing executive Andrew Chamlin will drive Aspargo Labs’ global growth in revolutionizing the way medications are delivered. New York, November 19, 2024 – Aspargo
Phase 1 study published in International Journal of Science and Research shows absorption of ASP-001 within 5 minutes, which is markedly faster than Viagra tablets
Dosing complete for 53 subjects in Sildenafil Oral Suspension Bioavailability Study Initiated dosing in 38 subjects in Sildenafil Oral Suspension Food-Effect Study Top-line data from
Study will compare bioavailability of Sildenafil Oral Suspension and Viagra® tablets under fasted conditions Companion study will evaluate the effects of food on the bioavailability
Company plans to initiate clinical trials in September 2023 to compare Sildenafil Oral Spray to Viagra® tablets, and effect of dose administration under fasted versus fed